Multiple myeloma (MM) is characterized by bone marrow infiltration with abnormal plasma cells which synthesize monoclonal immunoglobulins (Ig) or Ig fragments. Regularly, MM cells exhibit a high intrinsic resistance to available chemotherapeutic strategies. A number of cellular alterations including the cellular membrane, such as mutations of the glucocorticoid receptor or expression of membrane transport proteins, detoxification mechanisms and altered expression of topoisomerases, have been described. In addition to anti-apoptotic survival mechanisms, involving abnormalities of several oncogenes and suppressor genes (ras, c-myc, p53, Rh and bcl-2), the broad resistance spectrum might be explained but clinical studies which include the evaluation of resistance factors are missing. On the other hand, risk factor evaluation is important as a number of therapeutical strategies with different intensities from corticosteroid monotherapy up to high-dose chemotherapy with tandem autologous bone marrow transplantation exist.
Introduction
Despite three decades of clinical trials the number of true complete remissions in the therapy of multiple myeloma (MM) is still low, one of the main reasons being intrinsic or acquired cellular resistance. In this paper the knowledge of cellular resistance mechanisms is reviewed and the impact on therapeutic strategies discussed.
Biological background
Multiple myeloma is defined by bone marrow infiltration of neoplastic plasma cells that synthesize abnormal amounts of immunoglobulin (Ig) or Ig fragments. The target cell of malignant transformation in multiple myeloma is a B lineage cell which has already undergone antigenic selection. This conclusion can be drawn from the observation that somatic mutations which result in amino acid substitutions are frequent in the Ig variable region genes in MM, but intra-clonal variation has not been shown. 1 This B lineage cell probably corresponds to a pre-plasma cell or a plasma cell rather than a memory B cell. The myeloma cells are composed of immunophenotypically heterogeneous sub-populations at various stages of differentiation, similar to normal B lineage cells. This implies that there is an analogous developmental pathway between the normal B lineage cells and the myeloma cells.
Genetic alterations and oncogenes
Cytogenetic alterations are frequent in MM. In as many as 30% of patients hyper-diploidy and in 15% hypo-diploidy has been observed in a cytogenetic study of 151 patients. The most frequent numeric change was the loss of chromosome 13 which occurred in 15% of patients. 2 The oncogenes bcl-2 and H-ras seem to play exceptional roles in the transformation process of myeloma cells. Overexpression of the bcl-2 protein has been almost uniformly seen in clinical myeloma specimens as well as in myeloma cell lines. The failure to consistently identify a t(14;18) translocation implies a unique mechanism in MM.
3 T(14;18) translocations are frequently found in follicular lymphomas and are characteristically associated with over-expression of bcl-2, which has been linked to the inhibition of apoptotic response to chemotherapy. 4, 5 Mutated alleles of ras genes have been detected in a high percentage of myeloma patients in relapse phase.
6,7 A point mutated and activated H-ras oncogene, introduced in a human lymphoblastoid cell line, was able to induce neoplastic transformation and differentiation to plasma cells. This indicates a link between the ras mutations and the transformation to myeloma cells. 7 Ras mutations have been associated with cellular resistance to a number of cytostatics including doxorubicin and arabinoside. 8, 9 Cytokines and growth factors Excessive osteoclastic resumption is an early phenomenon of osteolytic bone lesions found in MM and a number of cytokines and growth factors such as IL-6, TNF, IL-1 beta, G-CSF and GM-CSF are probably involved. 10 Interleukin-6 (IL-6) seems to be of special importance for the generation of osteolytic bone lesion in MM. IL-6 is a multi-functional cytokine involved in the regulation of the terminal differentiation pathway of B lymphocytes. Thus, IL-6 is a potent myeloma cell growth factor.
11 There is some evidence that IL-6 influences progression of MM in an autocrine or paracrine manner and IL-6 serum levels are in correlation with disease activity, prognosis and survival.
12-15 IL-1 and TNF are able to induce IL-6 secretion by osteoclasts which stimulates the generation of new osteoclasts and bone resorption. 16 This cytokine network indicates a close relationship between MM cell stimulation and the induction of osteolytic bone lesions.
Besides IL-6, IFN-alpha is also a potent myeloma cell growth factor in vitro. It has been shown to stimulate the proliferation of most IL-6-dependent myeloma cell lines. IFNalpha can be used to induce autocrine production of IL-6 in myeloma cells and autonomously growing cell lines can be produced very quickly. 16 IFN-alpha is able to inhibit the production of the monoclonal component without affecting pro- liferation. 17 Therefore, IFN-alpha might mask an early relapse and the continuous injection of IFN-alpha in patients in early relapse might induce myeloma sub-clones with autocrine IL-6 production and worsen the disease. 16 IFN-gamma, on the other hand, acts as a potent inhibitor of myeloma cell proliferation by blocking the IL-6 receptor expression. A study by Portier et al 18 has also shown that IFN-gamma is able to inhibit cytokine-mediated bone resorption.
Steroid-receptor alterations
Despite their widespread use, little is known of either the mechanism of action of glucocorticoids in the treatment of multiple myeloma or why patients ultimately become resistant to their therapeutic effects. Moalli et al 19 have shown that resistance to dexamethasone can be induced in myeloma cell lines. The difference in the sensitive lines was the expression of a truncated glucocorticoid receptor mRNA resulting in a greatly reduced hormone-binding activity. The significance of this observation in clinical studies has not been examined.
P170-glycoprotein
Expression of the transmembrane P170-glycoprotein (P-gp) in MM has been investigated by several groups. [20] [21] [22] [23] [24] [25] [26] [27] The percentage of patients with P-gp overexpression at primary diagnosis ranged between 0 and 41%. [20] [21] [22] [23] The percentage of Pgp-positive patients at relapse or progression ranged between 29 and 59%. 24, 25 In our study 32% of the patients at primary diagnosis ( Table 1 ) and 33% of patients at relapse or progression were P-gp positive (Table 2) . (In our study we found Table 2 MM patients at relapse or progression according to response to VAD treatment and P-gp positivity by using the indirect immunocytological method with mAb 4.E3. 16 No. of patients (%) Response a positivity in Table 2 .) Six of 12 (50%) P-gp-negative MM patients at relapse or progression before VAD therapy developed P-gp overexpression after this regimen. All six MM patients did not respond, four patients demonstrated no change and two patients showed progression. No significant difference concerning survival time betgween P-gp-positive (median 25.4 months) and P-gp-negative (median 29.6 months) MM patients was seen. These data suggest that P-gp overexpression does not influence response to treatment significantly. The assumption that P-gp might be a crucial resistance mechanism was based upon early reports 20, 28, 29 and reactivated by the fact that prior exposure to vincristine and doxorubicin induces an increase in P-gp expression in human plasma cell myelomas. 22 Additionally, Sonneveld et al 21 demonstrated that cyclosporine, a so-called modulator of P-gp, has the potency to overcome chemotherapy refractoriness in MM patients. However, no relationship between P-gp expression and response to VAD treatment 24, 30 and no benefit from the modulator verapamil could be shown in larger trials. 30 On the other hand, the results of several studies indicate that P-gp modulators are able to restore the sensitivity of doxorubicin. [31] [32] [33] [34] [35] For the interpretation of these conflicting results a number of considerations must be taken into account. All treatment protocols including VAD (vincristine, doxorubicin and dexamethasone), VID (vincristine, idarubicin and dexamethasone) and VMD (vincristine, mitoxantrone and dexamethasone) contain corticosteroids which are highly effective drugs but not transported by P-gp. Moreover, no standardized methods are available which clearly define the amount of mdr1 gene expression or P-gp protein expression necessary to establish clinical relevance.
Glutathione S-transferase
Glutathione is involved in many biological functions including detoxification of alkylating agents and platinum complexes. Also, its activity has been connected to cellular melphalan resistance. 36 In a study by Ishikawa et al 23 16 of 21 (76%) myeloma cases showed significant expression of GSTpi protein and GST-pi mRNA. In another study, which included bone marrow samples from 40 patients, 72% of evaluated samples were positive for P-170 glycoprotein and 82% for GST-pi. A significant relationship between GST-pi expression and P-170 positivity was found and co-expression was observed in 91% of evaluated samples with an increase in relapse. 6 
Topoisomerase
Most of the resistant myeloma cell lines which are used for in vitro examination of resistance mechanisms have been produced by increasing concentrations of the selecting agent over a long period of time. This procedure does not reflect the clinical situation where chemotherapy is given in a repetitive schedule. Likely, the evolving cellular resistance mechanisms depend upon the selection method. In a co-operative study with Lehnert et al 37 from the Kantonspital in St Gallen, Switzerland, resistant myeloma cell lines using a quasi-therapeutical schedule have been selected. The sensitive myeloma cell line has been incubated with 5 nM or 10 nM doxorubicin for 4 days and then kept without drug for 17 days. This procedure was repeated for 18 months. Two resistant cell lines, named Dox-int5 and Dox-int10, emerged that showed a stable resistance for at least 6 months. As shown in Table 3 , the resulting resistance factors were not as high as in cell lines after continuous incubation with a predominance of topo-II-inhibitors and low resistance to melphalan or cisplatin. The differences between the dox-int5 cell line and the dox-int10 cell line were not high. In contrast to resistant cell lines selected by continuous exposure, neither MDR1 mRNA nor P170-glycoprotein expression were elevated as compared to the sensitive line, which can also be suspected by the low effect of verapamil on resistance. Topo-II alpha gene expression and activity was notably lower in both cell lines which might well explain the resistance to topo-II. 37 In clinical material, expression of topo-II mRNA was detected weakly in only one of 16 myeloma patients.
23

Possible clinical relevance
A characteristic feature of MM cells is their intrinsic resistance to available treatment modalities. Likely, the resistance is a consequence of an array of anti-apoptotic survival mechanisms involving abnormalities of several oncogenes and suppressor genes (ras, c-myc, p53, Rb, and bcl-2) in combination with cellular alterations which affect all cellular levels ( Figure 1 ). These include the cellular membrane, such as mutations of the glucocorticoid receptor or expression of membrane transport proteins, detoxification mechanisms and altered expression of topoisomerases. Whereas anti-apoptotic mechanisms affect the majority of chemotherapeutic strategies
Figure 1
Cellular resistance mechanisms in multiple myeloma.
resulting in a broad resistance spectrum, specific cellular resistance mechanisms might result in high resistance to certain drugs. However, the clinical relevance of the described resistance mechanisms cannot be weighted conclusively due to missing clinical studies which include evaluation resistance factors. On the other hand, risk factor evaluation is of significance for the patient as a number of therapeutical strategies from corticosteroid monotherapy up to high-dose chemotherapy with tandem autologous bone marrow transplantation exist.
Up to now it has been shown that certain cytogenetic abnormalities such as partial or complete deletion of chromosome 13 or abnormalities involving 11q 38 as well as proliferation-associated markers are coupled with poor outcome. Creactive protein (CRP р 4 mg/l), which reflects IL-6 activity, beta-2-microglobulin (␤ 2 M р 2.5 mg/l), in addition to no more than 1 year of prior therapy, presence of sensitive disease (Ͼ50% tumor mass reduction prior to transplant), and lactic dehydrogenase levels not exceeding 190 U/l are all independent favourable prognostic factors for event-free survival and overall survival. 39 Most of the studies presented concerning cellular resistance mechanisms have been performed using myeloma cell lines because in the majority of patient bone marrow infiltration by MM is low and the cells must either be selected or stimulated in vitro. Except for the study of Lehnert et al 37 resistant myeloma cell lines have been selected using increasing concentrations of the selecting agent over a long period of time. This procedure alters cellular biology and these in vitro results cannot be directly transferred into the clinical situation. For the development of individual riskadapted therapeutical strategies clinical studies which include the assessment of cellular resistance factors in clinical material are required.
